|
1
|
Torre LA, Bray F, Siegel RL, Ferlay J,
Lortet-Tieulent J and Jemal A: Global cancer statistics, 2012. CA
Cancer J Clin. 65:87–108. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Miyamoto Y, Nakagawa S, Wada-Hiraike O,
Seiki T, Tanikawa M, Hiraike H, Sone K, Nagasaka K, Oda K, Kawana
K, et al: Sequential effects of the proteasome inhibitor bortezomib
and chemotherapeutic agents in uterine cervical cancer cell lines.
Oncol Rep. 29:51–57. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Hernández-Hernández DM, Apresa-García T
and Patlán-Pérez RM: Epidemiological overview of uterine cervical
cancer. Rev Med Inst Mex Seguro Soc. 53 Suppl 2:S154–S161.
2015.PubMed/NCBI
|
|
4
|
Jiang WG, Sanders AJ, Ruge F and Harding
KG: Influence of interleukin-8 (IL-8) and IL-8 receptors on the
migration of human keratinocytes, the role of PLC-γ and potential
clinical implications. Exp Ther Med. 3:231–236. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Stronach EA, Cunnea P, Turner C, Guney T,
Aiyappa R, Jeyapalan S, de Sousa CH, Browne A, Magdy N, Studd JB,
et al: The role of interleukin-8 (IL-8) and IL-8 receptors in
platinum response in high grade serous ovarian carcinoma.
Oncotarget. 6:31593–31603. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Siegel R, Ma J, Zou Z and Jemal A: Cancer
statistics, 2014. CA Cancer J Clin. 64:9–29. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Ferlay J, Steliarova-Foucher E,
Lortet-tieulent J, Rosso S, Coebergh JW, Comber H, Forman D and
Bray F: Cancer incidence and mortality patterns in Europe:
Estimates for 40 countries in 2012. Eur J Cancer. 49:1374–1403.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Brat DJ, Bellail AC and Van Meir EG: The
role of interleukin-8 and its receptors in gliomagenesis and
tumoral angiogenesis. Neuro Oncol. 7:122–133. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Singh RK and Lokeshwar BL: The
IL-8-regulated chemokine receptor CXCR7 stimulates EGFR signaling
to promote prostate cancer growth. Cancer Res. 71:3268–3277. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Russo RC, Garcia CC, Teixeira MM and
Amaral FA: The CXCL8/IL-8 chemokine family and its receptors in
inflammatory diseases. Expert Rev Clin Immunol. 10:593–619. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Araki S, Omori Y, Lyn D, Singh RK,
Meinbach DM, Sandman Y, Lokeshwar VB and Lokeshwar BL:
Interleukin-8 is a molecular determinant of androgen independence
and progression in prostate cancer. Cancer Res. 67:6854–6862. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Sims LB, Curtis LT, Frieboes HB and
Steinbach-Rankins JM: Enhanced uptake and transport of
PLGA-modified nanoparticles in cervical cancer. J
Nanobiotechnology. 14:332016. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Shen L, Wen N, Xia M, Zhang YU, Liu W, Xu
YE and Sun L: Calcium efflux from the endoplasmic reticulum
regulates cisplatin-induced apoptosis in human cervical cancer HeLa
cells. Oncol Lett. 11:2411–2419. 2016.PubMed/NCBI
|
|
14
|
Gui SL, Teng LC, Wang SQ, Liu S, Lin YL,
Zhao XL, Liu L, Sui HY, Yang Y, Liang LC, et al: Overexpression of
CXCL3 can enhance the oncogenic potential of prostate cancer. Int
Urol Nephrol. 48:701–709. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Tsai YJ, Hao SP, Chen CL and Wu WB:
Thromboxane A2 regulates CXCL1 and CXCL8 chemokine expression in
the nasal mucosa-derived fibroblasts of chronic rhinosinusitis
patients. PLoS One. 11:e01584382016. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Liu Q, Li A, Tian Y, Wu JD, Liu Y, Li T,
Chen Y, Han X and Wu K: The CXCL8-CXCR1/2 pathways in cancer.
Cytokine Growth Factor Rev. 31:61–71. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Singh JK, Simões BM, Howell SJ, Farnie G
and Clarke RB: Recent advances reveal IL-8 signaling as a potential
key to targeting breast cancer stem cells. Breast Cancer Res.
15:2102013. View
Article : Google Scholar : PubMed/NCBI
|
|
18
|
Cianga CM, Cianga P, Dumitrescu GF and
Sava A: IL-8, IL-8RA (CXCR1) and IL-8RB (CXCR2) expression in
pilomatricoma. Rom J Morphol Embryol. 57:59–64. 2016.PubMed/NCBI
|
|
19
|
Fernando RI, Castillo MD, Litzinger M,
Hamilton DH and Palena C: IL-8 signaling plays a critical role in
the epithelial-mesenchymal transition of human carcinoma cells.
Cancer Res. 71:5296–5306. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Aravalli RN and Greten TF: FoxC1: Novel
regulator of inflammation-induced metastasis in hepatocellular
carcinoma. Gastroenterology. 149:861–863. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Wu D, Tao J, Ding J, Qu P, Lu Q and Zhang
W: Interleukin-11, an interleukin-6-like cytokine, is a promising
predictor for bladder cancer prognosis. Mol Med Rep. 7:684–688.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Xiao YC, Yang ZB, Cheng XS, Fang XB, Shen
T, Xia CF, Liu P, Qian HH, Sun B, Yin ZF and Li YF: CXCL8,
overexpressed in colorectal cancer, enhances the resistance of
colorectal cancer cells to anoikis. Cancer Lett. 361:22–32. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Mellado M, Rodríguez-Frade JM, Mañes S and
Martínez-A C: Chemokine signaling and functional responses: The
role of receptor dimerization and TK pathway activation. Annu Rev
Immunol. 19:397–421. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Liu F, Zheng S, Liu T, Liu Q, Liang M, Li
X, Sheyhidin I, Lu X and Liu W: MicroRNA-21 promotes the
proliferation and inhibits apoptosis in Eca109 via activating
ERK1/2/MAPK pathway. Mol Cell Biochem. 381:115–125. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Palena C, Hamilton DH and Fernando RI:
Influence of IL-8 on the epithelial-mesenchymal transition and the
tumor microenvironment. Future Oncol. 8:713–722. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Lake D, Corrêa SA and Müller J: Negative
feedback regulation of the ERK1/2 MAPK pathway. Cell Mol Life Sci.
73:4397–4413. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Bastida MF, Sheth R and Ros MA: A BMP-Shh
negative-feedback loop restricts Shh expression during limb
development. Development. 136:3779–3789. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Murphy C, McGurk M, Pettigrew J,
Santinelli A, Mazzucchelli R, Johnston PG, Montironi R and Waugh
DJ: Nonapical and cytoplasmic expression of interleukin-8, CXCR1,
and CXCR2 correlates with cell proliferation and microvessel
density in prostate cancer. Clin Cancer Res. 11:4117–4127. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
MacManus CF, Pettigrew J, Seaton A, Wilson
C, Maxwell PJ, Berlingeri S, Purcell C, McGurk M, Johnston PG and
Waugh DJ: Interleukin-8 signaling promotes translational regulation
of cyclin D in androgen-independent prostate cancer cells. Mol
Cancer Res. 5:737–748. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Venkatakrishnan G, Salgia R and Groopman
JE: Chemokine receptors CXCR-1/2 activate mitogen-activated protein
kinase via the epidermal growth factor receptor in ovarian cancer
cells. J Biol Chem. 275:6868–6875. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Luppi F, Longo AM, de Boer WI, Rabe KF and
Hiemstra PS: Interleukin-8 stimulates cell proliferation in
non-small cell lung cancer through epidermal growth factor receptor
transactivation. Lung Cancer. 56:25–33. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Kawamura M, Toiyama Y, Tanaka K, Saigusa
S, Okugawa Y, Hiro J, Uchida K, Mohri Y, Inoue Y and Kusunoki M:
CXCL5, a promoter of cell proliferation, migration and invasion, is
a novel serum prognostic marker in patients with colorectal cancer.
Eur J Cancer. 48:2244–2251. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Tosoni D, Zecchini S, Coazzoli M, Colaluca
I, Mazzarol G, Rubio A, Caccia M, Villa E, Zilian O, Di Fiore PP
and Pece S: The Numb/p53 circuitry couples replicative self-renewal
and tumor suppression in mammary epithelial cells. J Cell Biol.
211:845–862. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Sajadimajd S, Yazdanparast R and Akram S:
Involvement of Numb-mediated HIF-1α inhibition in
anti-proliferative effect of PNA-antimiR-182 in
trastuzumab-sensitive and -resistant SKBR3 cells. Tumour Biol.
37:5413–5426. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Faraldo MM and Glukhova MA: Regulating the
regulator: Numb acts upstream of p53 to control mammary stem and
progenitor cell. J Cell Biol. 211:737–739. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Sheng W, Dong M, Zhou J, Li X, Liu Q, Dong
Q and Li F: Cooperation among Numb, MDM2 and p53 in the development
and progression of pancreatic cancer. Cell Tissue. 354:521–532.
2013. View Article : Google Scholar
|
|
37
|
Rojas A, Liu G, Coleman I, Nelson PS,
Zhang M, Dash R, Fisher PB, Plymate SR and Wu JD: IL-6 promotes
prostate tumorigenesis and progression through autocrine
cross-activation of IGF-IR. Oncogene. 30:2345–2355. 2011.
View Article : Google Scholar : PubMed/NCBI
|
